Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab treat-to-target study using transmural healing versus clinical and biomarker targets in active Crohn's disease
NL-OMON60865Phase 4Recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vedolizumab in Crohn's disease (2 arms), sponsored by Alimentiv Inc. Primary endpoint: Corticosteroid-free endoscopic remission at Week 48. Started Jan 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON60865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60865.